Merck acquired the drug, called MK-7110, when it bought Oncolmunne, a private, clinical-stage drugmaker. In clinical trials, 75 percent of patients who received the drug showed a higher probability of improved clinical status compared to the placebo group. The drug also reduced the risk of death or respiratory failure by more than 50 percent.
Under the contract, if the drug receives emergency approval from the FDA, Merck is to make and supply the U.S. with 60,000 to 100,000 doses of the drug by June 30.
Read the full news release here.
More articles on pharmacy:
Pfizer, Moderna testing COVID-19 vaccines against UK variant
Retailers in mad rush to hire, bring back pharmacists
FDA investigating allergic reactions to Pfizer-BioNTech COVID-19 vaccine
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
